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Introduction
Large granular lymphocytic (LGL) leukemia is characterized
by an increased number of clonal cytotoxic T or natural killer
(NK) cells in blood and bone marrow.1 Concurrent neutrope-
nia, anemia, and autoimmune disorders, such as rheumatoid
arthritis, further support the diagnosis in unclear cases.2,3
Leukemic T-LGL cells are terminally differentiated effector
memory cells (CD3+CD45RA+CD62LnegCD57+) with clonal
rearrangement of the T-cell receptor (TCR) genes.4 According
to the World Health Organization (WHO) 2008 criteria,
chronic lymphoproliferative disease of NK cells (CLPD-NK) is
a separate entity and differs from aggressive, chemorefractory
NK-LGL leukemia.5
The phenotype of leukemic cells indicates that the expan-
sion originally developed in response to an antigen. However,
unlike their normal counterparts, leukemic LGL cells are
resistant to subsequent Fas-mediated activation-induced cell
death.6 A current hypothesis postulates that following antigen
encounter, the dysregulation of several signaling pathways
and cytokines such as interleukin-15, platelet-derived growth
factor receptor, and signal transducer and activator of tran-
scription 3 (STAT3) sustains a constitutively active clonal cell
population.6,7 The importance of these pathways has been
emphasized in the light of the recent discovery of somatic
mutations in STAT3 and STAT5b genes.8-13 The mutations
were located in the Src-like homologue 2 (SH2) domain of
STAT3 and STAT5b, caused constitutive phosphorylation of
the mutated proteins, and increased the transcriptional activ-
ity of STAT3 and STATb5 in vitro.8,9,14 Expression of mutated
STAT3 in mouse bone marrow led to the development of
myeloproliferative neoplasm, and recently similar STAT3 and
STAT5b mutations have also been discovered in other hema-
tologic malignancies.12,15-19
In this project we aimed to analyze the frequency of STAT3
mutations and the clonal architecture of expanded lympho-
cytes using both STAT3 and TCR beta (TCRB) chain deep
sequencing methods in a unique cohort of 213 patients with
LGL leukemia. In addition, the effect of immunosuppressive
treatment on the mutated clones was studied in follow-up
samples obtained during therapy to assess if quantitative
STAT3 mutation analysis could be used to monitor therapy
response.
Methods
Additional methods of this study are described in the
Online Supplementary Appendix.
Study patients
The study was undertaken in compliance with the principles of the
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T-cell large granular lymphocytic leukemia and chronic lymphoproliferative disorder of natural killer cells are intrigu-
ing entities between benign and malignant lymphoproliferation. The molecular pathogenesis has partly been uncov-
ered by the recent discovery of somatic activating STAT3 and STAT5b mutations. Here we show that 43% (75/174)
of patients with T-cell large granular lymphocytic leukemia and 18% (7/39) with chronic lymphoproliferative disor-
der of natural killer cells harbor STAT3 mutations when analyzed by quantitative deep amplicon sequencing.
Surprisingly, 17% of the STAT3-mutated patients carried multiple STAT3mutations, which were located in different
lymphocyte clones. The size of the mutated clone correlated well with the degree of clonal expansion of the T-cell
repertoire analyzed by T-cell receptor beta chain deep sequencing. The analysis of sequential samples suggested that
current immunosuppressive therapy is not able to reduce the level of the mutated clone in most cases, thus warrant-
ing the search for novel targeted therapies. Our findings imply that the clonal landscape of large granular lymphocytic
leukemia is more complex than considered before, and a substantial number of patients have multiple lymphocyte
subclones harboring different STAT3mutations, thus mimicking the situation in acute leukemia. 
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ABSTRACT
Helsinki declaration and was approved by the ethics committees
of Helsinki University Central Hospital (Finland), the Cleveland
Clinic (Ohio, USA) and the Penn State Hershey Cancer Institute
(Pennsylvania, USA). The study population consisted of 213
patients with LGL leukemia as defined by the WHO 2008 criteria:
174 patients had CD8+ T-LGL leukemia and 39 patients had
CLPD-NK. Samples were collected in the Penn State Hershey
Cancer Institute (n=93), the Cleveland Clinic (n=89), and Finland
(n=31). One hundred and twelve patients with T-LGL leukemia
and 30 with CLPD-NK included in the current study cohort were
also part of two previous study cohorts analyzing STAT3mutation
frequency by capillary sequencing.8,9 All patients gave written
informed consent to participation in this study.
Sample collection and DNA extraction
Mononuclear cells were separated from peripheral blood using
Ficoll gradient separation (GE Healthcare, Pittsburgh, PA, US,
USA) and cryopreserved in fetal bovine serum with 10%
dimethylsulfoxide. Peripheral blood mononuclear cells were
labeled with antibodies and sorted into CD4+ T-cell, CD8+ T-cell,
and NK-cell fractions using antibodies for CD3, CD4, CD8, and
CD16/56 (Beckton Dickinson, San Jose, CA, USA). In cases of T-
LGL leukemia, the CD8+ T-cell population was further sorted into
clonal/non-clonal cells based on the flow cytometry analysis of
TCRB variable chain (Vbeta) expression (IOTest® Beta Mark Kit,
Beckman Coulter, Brea, CA, US). DNA was extracted using a
NucleoSpin Tissue or Tissue XS kit (Macherey-Nagel, Dueren,
Germany) and the concentration was measured with Qubit (Life
Technologies, Carlsbad, CA, USA). 
Deep targeted sequencing and capillary sequencing 
of STAT3 exon 21
STAT3 exon 21 was sequenced using deep amplicon sequencing
and the Illumina Miseq platform as described previously.10 The
data were analyzed with a novel in-house bioinformatics pipeline,
which is based on calling of variants with certain count/frequency
and filtering out false positives using the estimated error rate and
quality data of amplicon reads. STAT3 amplicon sequencing and
data analysis are described in detail in the Online Supplementary
Appendix.  STAT3 exon 21 capillary sequencing was performed as
previously described.9
High-throughput T-cell receptor sequencing
TCRB complementarity determining regions (CDR3β) were
amplified and sequenced by Adaptive Biotechnologies Corp.
(Seattle, WA, USA) using ImmunoSEQ assay Survey level analysis,
which is capable of detecting one cell in 40,000 T cells.20 The
TCRB sequencing method is described in the Online Supplementary
Appendix.
Statistical analysis
Categorical variants between groups were compared using the
χ2 test. Comparisons of parametric variables between groups were
performed with one-way ANOVA and the Bonferroni post hoc
test, or unpaired t test, as appropriate. A P value <0.05 was consid-
ered statistically significant.
Results
STAT3-amplicon sequencing is a sensitive
and reliable method
Deep, targeted sequencing is a relatively new method
and we, therefore, first compared the sensitivity of ampli-
con sequencing with the well-established allele-specific
oligonucleotide (ASO) real-time quantitative polymerase
chain reaction (qPCR) method. The results of ASO-qPCR
for STAT3 mutations Y640F and D661V and amplicon
sequencing of STAT3 exon 21 were congruent in seven of
the eight cases analyzed (Online Supplementary Table S1).
The only discordant case (patient 14, Figure 1) was faintly
positive for Y640F by ASO-qPCR, but even the analysis of
sorted lymphocyte fractions did not show the Y640F
mutation by amplicon sequencing. 
As another quality control, we sequenced a dilution
series from a CD8+ peripheral blood mononuclear cell
sample (patient 9, Figure 1) with known STAT3 D661V
[variant allele frequency (VAF) 37%] and Y640F (VAF
1.4%) mutations in the CD8+ fraction: Y640F mutation
with low VAF was not seen in the original sequencing of
the peripheral blood mononuclear cell sample (Online
Supplementary Table S2, Figure 1). The D661V mutation
was detected at the 2% dilution level with a VAF of
0.633% (frequency ratio 0.896), whereas with the next
dilution of 1% and a VAF of 0.433% the frequency ratio
dropped under 0.8, being still on the borderline 0.75-0.80.
However, the noise exceeded the number of variant alleles
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Table 1. Clinical characteristics of the patients.
T-LGL leukemia (n=174) CLPD-NK1 (n=39)
Variable ≥2 STAT3-mutated 1 STAT3-mutated No STAT3 P All STAT3-mutated No STAT3 mutations P
clones (n=14) clone (n=61) mutations (n=99) (n=7) (n=32)
Median age (range) 67 (36-81) 65 (31-84) 66 (17-89) 0.72 68 (58-75) 57 (27-77) 0.077
Males (%) 13 (93%) 33 (54%) 57 (58%) 0.026 6 (86%) 19 (58%) 0.19
Median hemoblogin, g/L (range) 126 (87-154) 114 (74-165) 120 (59-172) 0.44 137 (58-159) 128 (69-168) 0.49
Median leukocytes, 109/L (range) 4.0 (0.8-27.2) 5.7 (1.0-24.8) 5.9 (1.2-28.5) 0.46 8.8 (4.1-15.0) 9.0 (1.8-21.4) 0.93
Median lymphocytes, 109/L (range) 3.0 (0.7-23.7) 3.4 (0.4-23.2) 3.2 (0.4-25) 0.15 7.0 (1.9-11.3) 6.0 (1.0-14.6) 0.78
Median neutrophils, 109/L (range) 0.6 (0.0-2.3) 1.2 (0.0-18.3) 1.6 (0.0-10.2) 0.24 1.3 (0.6-2.7) 1.3 (0.1-10.8) 0.37
Median platelets, 109/L (range) 217 (115-405) 181 (29-596) 215 (9-627) 0.31 245 (25-478) 208 (22-550) 0.69
Treatment (%)2 11 (79%) 43 (70%) 61 (62%) 0.16 3 (38%) 16 (48%) 1.00
Rheumatoid arthritis (%)3 6 (43%) 14 (23%) 6 (6%) <0.0001 NA NA
Laboratory values presented in the table were measured at diagnosis. Statistics are compared between three groups of patients (≥2 STAT3-mutated clones vs. 1 STAT3-mutated clone vs. unmu-
tated STAT3) in the case of T-LGL leukemia, and between two groups in CLPD-NK cases. 1Chronic lymphoproliferative disease of NK cells. 2Treatment at any timepoint during follow-up.
3Rheumatoid arthritis diagnosed at any timepoint during follow-up. Statistically significant differences are shown in bold.
and the mutation could not be reliably verified (Online
Supplementary Table S2). The 0.5% cut-off for VAF seemed
reasonable and was used in the following analysis.
As a negative control, we sequenced samples from eight
patients with chronic myeloid leukemia with clonal LGL
lymphocytosis during dasatinib treatment (a proportion of
dasatinib-treated patients with chronic myeloid leukemia
have drug-induced clonal LGL lymphocytosis).21,22 Sorted
monoclonal CD8+ expansions from four patients (CD8+
Vbeta clone size 10-69%) and total CD8+ fractions from
four additional cases (CD8+ Vbeta clone size 10-27%)
were analyzed by amplicon sequencing. All tested sam-
ples were STAT3 mutation-negative.
The frequency and pattern of STAT3 mutations 
in patients with large granular lymphocytosis leukemia
as determined by deep quantitative sequencing
The exon 21 of STAT3 gene was analyzed by both cap-
illary and amplicon sequencing from a cohort of 213 LGL
leukemia patients. DNA samples were extracted either
from whole blood, peripheral blood mononuclear cells,
or CD8+ T cells. The frequency of STAT3 mutations was
23% (50/213) by capillary sequencing and 38% (82/213)
by amplicon sequencing, showing the superiority of
amplicon sequencing as a screening assay. The mutations
were significantly more common in T-LGL leukemia
than in CLPD-NK (75/174, 43% versus 7/39, 18%;
P=0.0034).8,11 Capillary sequencing did not detect muta-
tions with VAF smaller than 9% (Figure 1, Online
Supplementary Table S3). The cohort of patients also
included 72 of the 77 T-LGL leukemia patients with a
large immunodominant clone (mean clone size 78%;
range, 32-99%) described in the original publication of
STAT3mutations in LGL leukemia,9 and the frequency of
STAT3 mutations was as high as 63% (45/72) by ampli-
con sequencing, compared to 43% by capillary sequenc-
ing. The mean clone size in the rest of the patients was
39% of CD8+ cells (range, 6-97%).  
A substantial proportion of patients with large granular
lymphocytic leukemia carry multiple STAT3 mutations 
In the amplicon sequencing analysis 22% (18 of 82) of
STAT3-mutated patients harbored multiple mutations in
the STAT3 gene (Figure 1). In 17/18 of the cases either
Y640 or D661 or both were mutated (Figure 1). As an
extreme example, two patients harbored four different
STAT3 mutations (Figure 1). Patients with multiple STAT3
mutations could be divided into two different groups
based on the allelic status derived from the amplicon data:
(i) patients harboring two single nucleotide variants in the
same STAT3 allele, resulting in one or two amino acid
changes (n=4, Figure 1, patients 1-4), and (ii) patients dis-
playing multiple STAT3 mutations in different alleles and
lymphocyte clones (n=14, Figure 1, patients 5-18). Thus,
Multiple STAT3 mutations in LGL leukemia
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Figure 1. STAT3 mutations and variant allele frequencies detected by
amplicon sequencing. The patients are grouped based on the num-
ber and allelic location of STAT3 mutations, and the LGL leukemia
type. STAT3 mutations detected also by capillary sequencing are
marked with “x” in the last column. NS: nonsense; VAF: variant allele
frequency. SNV: single nucleotide variants.
17% of STAT3-mutated cases (14 of 82) had multiple
mutated clones in the original screening.
Correlation of STAT3 mutations with clinical 
parameters
Intrigued by the finding of multiple STAT3 mutations,
we studied the correlation between the phenotype of the
patients and STAT3 mutation status to assess whether
multiple mutations would affect the clinical characteristics
of patients (Table 1). Rheumatoid arthritis, which is the
most common autoimmune manifestation in LGL
leukemia patients,23 was significantly more common in T-
LGL patients with one or multiple STAT3mutations: 43%
(6/14) of patients with multiple mutations and 23%
(14/61) with one mutation suffered from rheumatoid
arthritis compared to 6% (6/99) of patients without muta-
tions (P<0.0001) (Table 1). No statistical difference was
seen in the prevalence of rheumatoid arthritis between
patients with one or multiple STAT3 mutations (P=0.18).
Patients who had multiple STAT3-mutated clones were
almost exclusively males (13/14, 93%) (Table 1). The size
of the major expansion in TCR Vbeta analysis was greater
among patients with one STAT3 mutation than among
those without mutations (P<0.0001) (Figure 2A).
Neutropenia is often associated with LGL leukemia23, and
T-LGL leukemia patients with STAT3mutations had a ten-
dency toward lower neutrophil counts at diagnosis, but
the difference was not statistically significant (Table 1). No
significant clinical correlations were detected in the CLPD-
NK cohort, possibly due to the lower number of patients
(Table 1). 
The clinical picture was compared in more detail
between patients carrying the two most common muta-
tions, Y640F and D661Y (Figure 1). D661Y-mutated
patients had lower hemoglobin values at diagnosis (medi-
an 104 versus 122 g/L, P=0.0449), whereas they had higher
leukocyte and lymphocyte counts (12.4 versus 5.1 x106/L,
P=0.0440 and 7.5 versus 3.2 x106/L, P=0.0028, respectively)
(Figure 2B-D). 
STAT3 sequencing of sorted lymphocyte fractions
Screening for STAT3 mutations was performed on
unsorted samples, and the exact location of the mutations
and the clonal hierarchy were further analyzed in sorted
lymphocyte fractions. 
Patients with one STAT3 mutation have a monoclonal pattern 
in Vbeta analysis
First we sorted and analyzed samples from five T-LGL
leukemia patients with a monoclonal pattern in TCR
Vbeta analysis (clone size 27-81%) carrying a single STAT3
mutation in the original screening. In four of the five cases
the mutation was located in the major CD8+ Vbeta expan-
sion, and no other STAT3mutations were detected in sort-
ed lymphocyte fractions including CD4+ T cells, Vbeta
expansion-negative CD8+ cells, and CD3neg NK cells and B
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Figure 2. Comparison of differ-
ent clinical parameters
between patients with LGL
leukemia patients divided into
groups based on STAT3 muta-
tion status. Horizontal lines
define medians of measured
variables in all figures. (A) The
sizes of the largest clones in
CD8+ lymphocytes detected in
T-LGL leukemia patients by
flow cytometry (T-cell receptor
beta chain variable region
analysis). T-LGL patients were
divided into three groups: those
with ≥2 STAT3 mutation (data
available from 13 patients), 1
mutation (n=30) or no muta-
tions (n=62). Hemoglobin (B),
absolute leukocyte count (C)
and lymphocyte count (D) of T-
LGL leukemia patients with
either D661Y or Y640F muta-
tion were compared.
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cells (Figure 3A, Online Supplementary Figure S1). In one
case (patient 48, Figure 1), in addition to the N647I-mutat-
ed major Vb21.3+ expansion, three low VAF mutations
were detected in the sorted Vb21.3neg CD8+ fraction, which
were not discovered in the original screening (Figure 3B).
Multiple STAT3 mutations in sorted lymphocytes
A similar analysis was done on cells from two T-LGL
leukemia patients who harbored a set of multiple STAT3
mutations already in the original screening (Figure 3C,
Online Supplementary Figure S1). The patients carried
STAT3 mutations in both detected Vbeta expansions and,
in addition, an apparently non-clonal CD8+ population
from patient 7 contained two additional mutations,
N647Y and D661V (Figure 3C). CD4+ and CD3neg lympho-
cyte fractions did not harbor STAT3 mutations.
Comparison of clonality analysis by STAT3 and deep 
T-cell receptor beta chain sequencing
Detailed analysis of TCRB CDR3 region rearrangement
and clonality was performed in paired samples from three
T-LGL leukemia patients who had multiple STAT3 muta-
tions. The patients were not HLA-matched. We assumed
that in the case of a heterozygous STAT3 mutation, the
size of the mutated clone determined by deep TCRB
sequencing would be approximately twice the STAT3
mutation VAF. The number of TCRB CDR3 reads for each
sample is shown in Online Supplementary Table S4.
Deep T-cell receptor beta chain sequencing results are 
in concordance with the STAT3 mutation analysis
The results of deep TCRB sequencing were in concor-
dance with STAT3 mutation analysis, and they also
explained the observed differences between clone size
analysis (flow cytometry) and STAT3 amplicon sequenc-
ing. Patient 8, who had Y640F-mutated Vb3+ expansion in
the Vbeta flow analysis, correspondingly had one major
expansion in the sorted Vb3+ fraction (73% of TCRB
sequences) (Figure 4A, Online Supplementary Table S5).
The Vb3neg fraction was also abnormally skewed and con-
sisted of a single clonal TCRB sequence (74% of reads),
which explains the high VAF (25-35% at different time-
points) of STAT3 I659L in the Vb3neg fraction (Figure 4A).
The TCRB rearrangement observed in the Vb3neg fraction
also appeared in the sorted Vb3+ sample, due to impurity
of the sorting (86% of sorted cells were Vb3+) (Figure 4A). 
Patient 48 had a large Vb21.3+ clone in Vbeta flow
analysis, but the VAF of N647I was only 34% in the sort-
ed Vb21.3+ fraction. The sorted Vb21.3+ population was
dominated by a clonal TCRB rearrangement that covered
63% of TCRB sequences, corresponding to the estimated
percentage of STAT3-mutated cells from amplicon
sequencing (2xVAF of 33%), but in addition, 26% of the
sequences came from another rearrangement with the
TCRBV20-01 gene (Figure 4B). Interestingly, based on the
flow cytometry purity analysis the sorted Vb21.3+ frac-
tion seemed monoclonal and contained only Vb21.3+
cells, so both clones with different amino acid sequences
were recognized by the same Vbeta antibody (Table 2).
The Vb21.3neg population was less skewed: the largest
productive TCRB rearrangements were 4%, 2% and 2%
of sequences, and probably contained the STAT3 muta-
tions detected in the Vb21.3neg fraction (Figure 4B, Online
Supplementary Table S5).
Multiple STAT3 mutations in LGL leukemia
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Figure 3. The flow cytometry
Vbeta analysis and STAT3-
sequencing results of flow
cytometry-sorted lymphocyte
fractions from three repre-
sentative T-LGL leukemia
patients. The monoclonal
Vbeta antibodies were conju-
gated with either FITC (x-axis),
PE (y-axis), or both PE and
FITC (double-positive popula-
tion), and the Vbeta popula-
tions analyzed are marked in
each dotplot with the per-
centage of the clone in CD8+
cells. STAT3 mutations and
their VAF are indicated with
arrows. (A) The results of
patient 69 after 1.5 years
after cyclosporine treatment.
(B) STAT3 results of patient
48 with four different STAT3
mutations. (C) Patient 7
(Figure 1) had two CD8+
expansions at baseline,
Vb7.1+ 10% and Vb5.1 11%
(data not shown), and 4 years
later during methotrexate
treatment the expansions
were 3% and 13%, respec-
tively, both harboring STAT3
mutations. This patient also
had two minor STAT3 muta-
tions in Vbeta-negative CD8+
cells. FITC: fluorescein isoth-
iocyanate; PE: phycoerythrin;
VAF: variant allele frequency.
C
BA Patient 69 Patient 48
Patient 7
no STAT3
mutations
Y640F 44%
N647I 33%
D661Y 34%
Y640F 35%
Y640F 0.7%
N647Y 3%
D661V 4%
Y640F 4%
N661V 0.8%
D661Y 0.5%
D661Y 6%
N647I 5%
D661V 3%
Patient 14 had two CD8+ expansions (Online
Supplementary Figure S1) and the TCRB analysis of the larg-
er one (Vb17+) showed that 83% of TCRB rearrangement
sequences were of a single clone, again corresponding well
to the VAF (41%) of the D661V mutation (Online
Supplementary Figure S1, Online Supplementary Table S5). A
smaller D661Y-mutated Vb13.6+ clone accounted for 11%
of CD8+ cells in Vbeta analysis, but TCRB sequencing
could not be done due to the low amount of Vb13.6+
DNA. A corresponding TCRB sequence was seen in the
analysis of the CD3+ fraction (Online Supplementary Figure
S1, Online Supplementary Table S5).
STAT3-mutated clones did not share homologous T-cell receptor
beta chain sequences
In the comparison of the 20 most frequent TCRB CDR3
amino acid sequences of each patient, all sequences were
unique and not present in either of the two other cases
(data not shown). A similar analysis of the clones shown in
Online Supplementary Table S5 was done between patients
and 586 healthy individuals (peripheral blood mononu-
clear cells sequenced, provided by the Adaptive
Biotechnologies), and in each LGL leukemia case at least
one of the leukemic clones was seen in the healthy con-
trols (the prevalence of the amino acid sequence varied
between 0-20% in the healthy control dataset, Online
Supplementary Table S5). However, the frequencies of these
amino acid sequences in individual healthy control sam-
ples were low (0.0001-0.005%), corresponding to a single
cell per sample.
In the case of multiple STAT3-mutated clones within
each patient, the sequences were not apparently homolo-
gous, although interestingly the flow cytometry Vbeta
antibody recognized two rearrangements in the Vb21.3+
fraction of patient 48, suggesting that although the amino
acid sequences in the CDR3 region are dissimilar, they
may share some homology in the three-dimensional
structure of the receptors (Figure 4B, Online Supplementary
Table S5). 
STAT3 mutation analysis can be used in the follow-up
of response to treatment
Sequential samples were available for STAT3 mutation
analysis from six patients including patients with one
(n=3) or multiple (n=3) STAT3 mutations. Four patients
were diagnosed with T-LGL leukemia, one with CLPD-
H.L.M. Rajala et al.
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Figure 4. Flow cytometry Vbeta analysis results and TCRB CDR3 repertoire landscape of two T-LGL leukemia patients. STAT3 mutation VAF are
shown in the titles of the analyzed fractions. (A) Patient 8 had one major Vb3+ expansion (93%) in Vbeta analysis, corresponding to the major
TCRB rearrangement in the sorted Vb3+ fraction. Vb3neg fraction appeared polyclonal in the Vbeta analysis, but TCRB sequencing revealed a
single major TCRB clone. The TCRB rearrangement observed in the Vb3neg fraction was also present in the sorted Vb3+ sample, due to impurity
of the sorting (86% of sorted cells were Vb3+). (B) Patient 48 presented with a monoclonal pattern in Vbeta analysis, but TCRB analysis of flow
cytometry-sorted Vb21+ cells revealed two TCRB rearrangements with different amino acid sequences, recognized by the same monoclonal
antibody, whereas the Vb21neg fraction of the same patient showed only minor TCRB rearrangements. CDR3: complementarity determining
region 3; TCRB: T-cell receptor beta chain; VAF: variant allele frequency.
B
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NK, and one patient had both T- and NK cell expansions.
Patients were treated with either methotrexate (n=2) or
cyclophosphamide (n=3) and one patient was untreated.
The median follow-up time was 33 months (range, 24-62). 
Patient 4 was untreated, and developed anemia and neu-
tropenia during a follow-up of 28 months: the CD8 per-
centage increased slightly concomitantly with the devel-
opment of cytopenias, but the mutated leukemic clone
was unchanged and no new STAT3 mutations evolved
(Figure 5A). 
The mutated clone(s) persisted during the course of
therapy in two T-LGL leukemia patients treated with
methotrexate, although improvement of hemoglobin val-
ues was observed in both cases during immunosuppres-
sion (Figure 5B, Online Supplementary Figure S2). However,
the partial response achieved was lost after the cessation
of methotrexate in the case of patient 8 (Figure 5B). 
The disappearance of STAT3-mutated clones was asso-
ciated with complete remission in two patients treated
with cyclophosphamide (Figure 5C, Online Supplementary
Figure S2). In both cases STAT3 mutation status was the
only reliable marker of clonality, as both patients had an
aberrant leukemic CD3negCD19negCD16/56neg NK-LGL pop-
ulation carrying a STAT3 mutation (Figure 5C, Online
Supplementary Figure S2). In the case of patient 44, D661Y-
mutated NK-LGL cells were suppressed and normal NK
cells were restored at complete remission (Figure 5C). The
third patient treated with cyclophosphamide developed
marked cytopenias during treatment, and no change was
observed in the immunodominant STAT3-mutated clone
(Online Supplementary Figure S2).
Discussion
Next generation sequencing methods have enabled the
discovery of the molecular background and clonal hierar-
chy of many hematologic malignancies. Although LGL
leukemia differs from acute leukemia, our results show
that clonal diversity also plays a role in the former. To our
surprise, 17% of all LGL leukemia patients with STAT3
mutations had multiple mutations in the STAT3 gene
residing solely in cytotoxic CD8+ or NK cells. The initial
mutation-causing event remains undiscovered, but the
combined results from TCRB deep sequencing and STAT3
mutation analysis suggest that a polyclonal immune
response may lay the foundation for mutagenesis.
Ultra-deep amplicon sequencing is a novel method for
mutation screening, quantitative analysis of the mutated
clones, and monitoring of disease burden. Based on our
results, the data obtained from amplicon analysis is in
good accordance with ASO-qPCR data, and the assay can
reliably detect clones down to a VAF threshold of 0.5%,
even though higher sensitivities may be reached with
ASO-qPCR assays. Compared to ASO-qPCR, the ampli-
con method can cover a larger part of the gene (one exon,
for example, in the case of STAT3) and identify previously
unknown mutations in a single run, whereas ASO-qPCR is
based on mutation-specific primers. However, ASO-qPCR
may provide data on common mutations quickly without
the need for next-generation sequencing facilities. With
the amplicon method, the STAT3mutation frequency was
38% in our whole LGL leukemia cohort and significantly
higher (over 60%) when only patients with large immun-
odominant clones were analyzed. Based on these results it
is likely that the diagnosis of LGL leukemia made accord-
ing to WHO criteria may include different disease sub-
types and in some cases also reactive LGL proliferations.
Similarly, previous studies have shown that the prevalence
of STAT3 mutations can be as high as 40-70% in T-LGL
leukemia, when patients with monoclonal expansions are
studied.9,11 STAT3mutations are only rarely found in other
hematologic malignancies.12,15,17,24,25
The reason for the high incidence of STAT3mutations in
Multiple STAT3 mutations in LGL leukemia
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Figure 5. STAT3 sequencing results and clinical data of three repre-
sentative LGL leukemia patients. In each case the first figure shows
the size of the LGL clone and VAF of STAT3 mutation at different time-
points, and the second figure presents the hematologic parameters.
(A) The results of untreated patient 4, who developed anemia and
neutropenia before the initiation of methotrexate (MTX) treatment.
(B) Patient 8 was treated with MTX. Leukemic STAT3-mutated clones
persisted during MTX therapy, and the patient developed anemia
after cessation of the therapy. (C) Patient 44 had an aberrant STAT3-
mutated CD3negCD16/56neg NK-LGL population, which was sup-
pressed during remission achieved by cyclophosphamide (CTX) treat-
ment simultaneously with restoration of normal NK cells. In addition,
the patient had two CD8+ clones with unmutated STAT3: the Vb20+
clone was suppressed during CTX administration, whereas Vb8+ cells
were first seen during complete remission. At the last timepoint the
number of NK-LGL cells was too low for DNA extraction and STAT3
mutation analysis. Tx: therapy; VAF: variant allele frequency.
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LGL leukemia is unknown. In the detailed analysis of LGL
populations, the occurrence of STAT3 mutations was
restricted to expanded lymphocyte clones. During CD8
memory cell development, the STAT3 pathway is activat-
ed, and it may be exposed to mutagenesis during an initial
polyclonal cell proliferation.26,27 As the STAT3 mutations
in LGL leukemia are gain-of-function mutations and are
able to cause leukemic transformation in multiple set-
tings,8,9,14,15 they may give a survival advantage to affected
cells, leading to a narrowing of the TCR repertoire and
expansion of certain clones. In most cases, patients with
multiple mutations had one immunodominant clone and
additional smaller expansions, indicating that the clones
may have different proliferation capacity or apoptotic
resistance, which could be due to the activation potential
or temporal variation in the occurrence of the STAT3
mutation in question. The presence of several STAT3
mutations could also be related to the clonal drift phe-
nomenon, where the immunodominant LGL clone
changes.28 In addition, STAT3-mutated clones may carry
somatic mutations in other genes, which affect the prolif-
erative capacity of affected lymphocytes. These muta-
tions could also drive the lymphoproliferation in patients
without STAT3mutations.29,30 However, it is interesting to
speculate that other factors such as a dysregulated
immune system may be needed to sustain the leukemic
LGL expansion. In a proportion of cases, these other
abnormalities can even lead to the development of LGL
leukemia without a somatic driver mutation. This
hypothesis is strengthened by a recent study showing
that the activated interleukin-6-STAT3 loop had a signifi-
cant role in the pathogenesis of LGL leukemia independ-
ently of STAT3 mutation status.31
The association between rheumatoid arthritis and multi-
ple STAT3 mutations in our cohort of patients points
toward the involvement of chronic antigen stimulation in
the pathogenesis of T-LGL leukemia. Based on our hypoth-
esis polyclonal T cells with autoreactive TCR may represent
the starting point for multiple mutated clonal expansions
and for rheumatoid arthritis, but other factors are also likely
to contribute. In our patients we were not able to address
whether in most cases rheumatoid arthritis preceded the
diagnosis of LGL leukemia or vice versa, but in previous
studies, symptomatic rheumatoid arthritis was demonstrat-
ed to occur either concurrently or prior to LGL leukemia.32,33
Further studies with paired follow-up samples and geneti-
cally modified mouse models are warranted to understand
the detailed pathomechanism and the relation of STAT3
mutation formation with rheumatoid arthritis.
The deep TCRB sequencing data showed that the
results of STAT3 mutation analysis were in good accor-
dance with the sizes of the clonal CDR3 rearrangements.
STAT3-mutated clones did not share TCRB CDR3 homol-
ogy even in the case of multiple STAT3 mutations in the
same patient. However, identical amino acid sequences
could be found at a low frequency in healthy controls sug-
gesting that they are common TCR sequences. It was
established earlier that the major clones in CD8+ T-LGL
leukemia patients are rarely identical, but the immuno -
dominant clones are sometimes seen at a low frequency in
other patients when the whole TCRB repertoire is ana-
lyzed.28,34-36 It should, however, be noted that the specific
antigen can be recognized by a large number of different
TCR types depending on the peptide presented, and the
variation of HLA genes also affects antigen recognition.37,38
The presence of a shared antigen driving the LGL prolifer-
ation has not, therefore, been ruled out, although our cur-
rent understanding suggests more private antigens.
During the past years LGL leukemia patients have pri-
marily been treated with immunosuppressive regimens
with unsatisfactory results, and over half of the patients
relapse on therapy.3 In clinical studies, the evaluation of
response to treatment has included mainly the follow-up
of hematologic parameters and TCR PCR testing, both of
which are relatively insensitive and unspecific approaches.
STAT3 amplicon sequencing provides a new method to
analyze treatment response, and it generates quantitative
data on the clone sizes. Although the number of patients
we analyzed was relatively small, the sizes of the STAT3-
mutated clones were in good accordance with clinical
results, and the findings may explain why patients relapse.
For example, patients treated with methotrexate did not
show a marked change in the size of the mutated clone
during the observation period. The initial partial responses
achieved may be due to the immunosuppressive effect of
methotrexate on cytotoxic cell function, but methotrexate
therapy is not able to eradicate the mutated clone.
Interestingly though, the mutated clones disappeared in
two patients who went into complete remission during
cyclophosphamide treatment. Concordantly, recent
results support the use of cyclophosphamide as a first-line
therapy: the overall response rate was 71% (complete
response 47%) and relapses were rarely observed.39 Low
relapse rates could be related to the ability of cyclophos-
phamide to eradicate LGL clones, but further studies with
larger patient cohorts are needed to confirm the prelimi-
nary findings.
To conclude, ultra-deep STAT3 amplicon sequencing is a
reliable method, which can be used in diagnostics and
treatment response evaluation in LGL leukemia. A signifi-
cant proportion of LGL leukemia patients have multiple
STAT3-mutated lymphocyte clones mimicking the clonal
diversity observed in patients with acute leukemia.
Sequential analysis of samples suggested that the current
immunosuppressive therapy is not able to eradicate the
STAT3-mutated clones and novel targeted therapies are,
therefore, needed to improve treatment results. 
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